Concepedia

Results of a Phase II Multicenter Trial of Pentostatin and Rituximab in Patients with Low-Grade B-Cell Non-Hodgkin's Lymphoma: An Effective and Minimally Toxic Regimen

Robert Drapkin, Nicholas J. Di Bella, D Faragher, Elizabeth Harden, Carmen Matei, William Hyman, Mae Y. Mirabel, Kristi A. Boehm, Lina Asmar

Clinical Lymphoma · 2003 · 19 citations · 31 references

DOI

Concepts

References

31

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

Thomas A. Davis, Antonio J Grillo-López, Christine A. White et al. · Journal of Clinical Oncology · 2000 · 688 citations

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

Philippe Colombat · Blood · 2001 · 523 citations

Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma

John D. Hainsworth, Sharlene Litchy, Howard A. Burris et al. · Journal of Clinical Oncology · 2002 · 417 citations

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

D. Huhn · Blood · 2001 · 348 citations · Full text